(Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today ...

Barclays on Thursday downgraded the contract research organizations IQVIA Holdings (NYSE:IQV), ICON PLC (NASDAQ:ICLR), and Fortrea Holdings (NASDAQ:FTRE), arguing that the Trump administration’s ...

Corporation announces the submission of its next-generation blood volume analyzer – Daxor BVA – to the Food and Drug ...

A recently developed medication encourages people with cocaine use disorder to reduce their intake of the stimulant – a step ...

BOGOTA (Reuters) - Carlos Lehder, former drug trafficker and one of the founding leaders of the Medellin Cartel, was arrested on Friday by Colombian authorities upon his arrival from Germany on a ...

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...

What are records? Since 2014, The Marshall Project has been curating some of the best criminal justice reporting from around the web. In these records you will find the most recent and the most ...

Fortunately, the S&P 500 recovered to new all-time highs by August 2020 and is now up about 150% from its COVID lows. Unfortunately, there are a handful of quality stocks that have missed out on the ...

The effectiveness of the SMPOP service was evaluated based on prescription appropriateness, adverse drug reactions (ADRs), length of hospital ... points in the medication management process and ...

In this article, we are going to take a look at where ICON Public Limited Company (NASDAQ:ICLR) stands against the other AI stocks. As the global AI race heats up with rapid developments in Asia ...

ICON Public Limited Company (NASDAQ:ICLR) announced it would begin utilizing clinical trial solutions provider Medidata’s AI-based Clinical Data Studio to advance its studies, optimize clinical ...

US-based pharmaceutical giant Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, following approval from the Central Drugs Standard Control Organisation (CDSCO).